不可复性牙髓炎的活髓保存治疗:生物学基础与临床进展

doi:10.13591/j.cnki.kqyx.2024.06.001

口腔医学 ›› 2024, Vol. 44 ›› Issue (6): 401-407.doi: 10.13591/j.cnki.kqyx.2024.06.001

• 述评 • 下一篇

不可复性牙髓炎的活髓保存治疗:生物学基础与临床进展

刘红艳,郑思怡,韦曦()

中山大学附属口腔医院·光华口腔医学院牙体牙髓病科,广东省口腔疾病临床医学研究中心,广东广州(510055)

收稿日期:2024-03-20 出版日期:2024-06-28 发布日期:2024-06-27
通讯作者: 韦曦 E-mail:weixi@mail.sysu.edu.cn
作者简介:韦曦,教授、主任医师、博士研究生导师。现任中山大学附属口腔医院·中山大学光华口腔医学院牙体牙髓病科主任、中华口腔医学牙体牙髓病学专业委员会副主任委员、广东省口腔医学会牙体牙髓病学专业委员会主任委员、国家医师资格考试口腔类别试题开发专家委员会委员。主要从事龋病微生态防治、牙髓损伤修复机制的研究,擅长牙体牙髓疾病的显微与数字化治疗。发表论文200余篇,其中SCI收录89篇,主编、副主编专著6部,参编专著教材等8部。主持国家自然科学基金6项,获省部级科技进步奖7项,省级教学成果一等奖3项。
基金资助:
国家自然科学基金(82370943);广州地区临床重大技术项目(2023P-ZD07);2022年度广东省本科高校教学质量与教学改革工程项目[课程教研室(虚拟教研室)](粤教高函[2023]4号)

New advances in vital pulp therapy for the treatment of irreversible pulpitis: From biological basic to clinical perspective

LIU Hongyan,ZHENG Siyi,WEI Xi()

Department of Operative Dentistry and Endodontics, Hospital of Stomatology, Guanghua School of Stomatology, Sun Yatsen University & Guangdong Provincial Clinical Research Center of Oral Diseases,Guangzhou 510055, China

Received:2024-03-20 Online:2024-06-28 Published:2024-06-27

1. 导读视频.mp4(3686KB)

摘要/Abstract

摘要：

保存牙髓活力、维持根尖周组织的健康、进行最小程度的有创性治疗是当代牙髓病学发展的前沿进展。不可复性牙髓炎是牙髓病学的重要研究内容之一。活髓保存治疗在不可复性牙髓炎领域中的应用与探索,有望推动牙髓炎诊疗的精准化、微创化进程。本文对活髓保存治疗在不可复性牙髓炎诊断、治疗等方面的应用及面临的挑战进行系统阐述。

关键词: 活髓保存, 不可复性牙髓炎, 牙髓切断, 诊断, 治疗

Abstract:

Preserving the sustained vitality of dental pulp, maintaining the periapical tissues in a healthy state and implementing minimally invasive therapies are key themes within the development of contemporary endodontics. The research of irreversible pulpitis is of great importance within endodontics. The application and investigation of vital pulp therapy(VPT)in the field of irreversible pulpitis is expected to facilitate the precision and minimally invasive process in diagnosis and treatment of pulpitis. This review article focuses on the application of vital pulp therapy in the diagnosis and treatment of irreversible pulpitis as well as the challenges.

Key words: vital pulp therapy, irreversible pulpitis, pulpotomy, diagnosis, treatment

中图分类号:

R781.3

刘红艳, 郑思怡, 韦曦. 不可复性牙髓炎的活髓保存治疗:生物学基础与临床进展[J]. 口腔医学, 2024, 44(6): 401-407.

LIU Hongyan, ZHENG Siyi, WEI Xi. New advances in vital pulp therapy for the treatment of irreversible pulpitis: From biological basic to clinical perspective[J]. Stomatology, 2024, 44(6): 401-407.

图/表 1

参考文献 61

[1]	AAE. AAE Consensus Conference recommended diagnostic terminology[J]. J Endod, 2009, 35(12):1634.
[2]	周学东. 牙体牙髓病学[M]. 5版. 北京: 人民卫生出版社, 2020: 163-164.
[3]	Taha NA, Abdelkhader SZ. Outcome of full pulpotomy using Biodentine in adult patients with symptoms indicative of irreversible pulpitis[J]. Int Endod J, 2018, 51(8):819-828. doi: 10.1111/iej.12903 pmid: 29397003
[4]	Taha NA, Abdulkhader SZ. Full pulpotomy with biodentine in symptomatic young permanent teeth with carious exposure[J]. J Endod, 2018, 44(6):932-937. doi: S0099-2399(18)30165-1 pmid: 29681479
[5]	Uesrichai N, Nirunsittirat A, Chuveera P, et al. Partial pulpotomy with two bioactive cements in permanent teeth of 6- to 18-year-old patients with signs and symptoms indicative of irreversible pulpitis: A noninferiority randomized controlled trial[J]. Int Endod J, 2019, 52(6):749-759. doi: 10.1111/iej.13071 pmid: 30638262
[6]	Ramani A, Sangwan P, Tewari S, et al. Comparative evaluation of complete and partial pulpotomy in mature permanent teeth with symptomatic irreversible pulpitis: A randomized clinical trial[J]. Int Endod J, 2022, 55(5):430-440.
[7]	Tzanetakis GN, Papanakou S, Koletsi D, et al. Outcome of partial pulpotomy in immature permanent teeth with symptomatic irreversible pulpitis: A prospective case series assessment[J]. J Endod, 2023, 49(9):1120-1128.
[8]	Tzanetakis GN, Koletsi D, Georgopoulou M. Treatment outcome of partial pulpotomy using two different calcium silicate materials in mature permanent teeth with symptoms of irreversible pulpitis: A randomized clinical trial[J]. Int Endod J, 2023, 56(10):1178-1196.
[9]	Aldeen RZ, Aljabban O, Almanadili A, et al. The influence of carious lesion and bleeding time on the success of partial pulpotomy in permanent molars with irreversible pulpitis: A prospective study[J]. Bioengineering(Basel), 2023, 10(6):700.
[10]	Sheng M, Zhang DH, Yan J, et al. Relationship between time to hemostasis and outcomes of pulpotomy using iRoot BP Plus in symptomatic young permanent teeth: A prospective study[J]. J Clin Pediatr Dent, 2023, 47(6):142-149. doi: 10.22514/jocpd.2023.088 pmid: 37997245
[11]	Jassal A, Nawal RR, Yadav S, et al. Outcome of partial and full pulpotomy in cariously exposed mature molars with symptoms indicative of irreversible pulpitis: A randomized controlled trial[J]. Int Endod J, 2023, 56(3):331-344.
[12]	Taha NA, Abuzaid AM, Khader YS. A randomized controlled clinical trial of pulpotomy versus root canal therapy in mature teeth with irreversible pulpitis: Outcome, quality of life, and patients’ satisfaction[J]. J Endod, 2023, 49(6):624-631. e2.
[13]	Cushley S, Duncan HF, Lappin MJ, et al. Pulpotomy for mature carious teeth with symptoms of irreversible pulpitis: A systematic review[J]. J Dent, 2019, 88: 103158.
[14]	Jang JH, Shin HW, Lee JM, et al. An overview of pathogen recognition receptors for innate immunity in dental pulp[J]. Mediators Inflamm, 2015, 2015: 794143.
[15]	何文喜, 余擎. 牙髓炎的活髓保存及再生治疗新进展:从基础到临床[J]. 中华口腔医学杂志, 2022, 57(1):16-22.
[16]	Islam R, Islam MRR, Tanaka T, et al. Direct pulp capping procedures-evidence and practice[J]. Jpn Dent Sci Rev, 2023, 59: 48-61.
[17]	Lin LM, Ricucci D, Saoud TM, et al. Vital pulp therapy of mature permanent teeth with irreversible pulpitis from the perspective of pulp biology[J]. Aust Endod J, 2020, 46(1):154-166. doi: 10.1111/aej.12392 pmid: 31865629
[18]	Ricucci D, Loghin S, Lin LM, et al. Is hard tissue formation in the dental pulp after the death of the primary odontoblasts a regenerative or a reparative process?[J]. J Dent, 2014, 42(9):1156-1170. doi: 10.1016/j.jdent.2014.06.012 pmid: 25008021
[19]	Ricucci D, Loghin S, Jr Siqueira JF. Correlation between clinical and histologic pulp diagnoses[J]. J Endod, 2014, 40(12):1932-1939. doi: 10.1016/j.joen.2014.08.010 pmid: 25312886
[20]	Skitioui M, Seck A, Niang SO, et al. The treatment of mature permanent teeth with irreversible pulpitis by cervical pulpotomy: A systematic review[J]. Aust Endod J, 2023, 49(Suppl 1):488-493.
[21]	周学东, 黄定明, 刘建国, 等. 牙髓损伤的活髓保存治疗[J]. 华西口腔医学杂志, 2017, 35(4):339-347.
[22]	European Society of Endodontology developed by:, Duncan HF, Galler KM, et al. European Society of Endodontology position statement: Management of deep caries and the exposed pulp[J]. Int Endod J, 2019, 52(7):923-934. doi: 10.1111/iej.13080 pmid: 30664240
[23]	AAE. AAE position statement on vital pulp therapy[J]. J Endod, 2021, 47(9):1340-1344. doi: 10.1016/j.joen.2021.07.015 pmid: 34352305
[24]	Kahler B, Taha NA, Lu J, et al. Vital pulp therapy for permanent teeth with diagnosis of irreversible pulpitis: Biological basis and outcome[J]. Aust Dent J, 2023, 68(Suppl 1):S110-S122.
[25]	Santos JM, Pereira JF, Marques A, et al. Vital pulp therapy in permanent mature posterior teeth with symptomatic irreversible pulpitis: A systematic review of treatment outcomes[J]. Medicina(Kaunas), 2021, 57(6):573.
[26]	Ballal NV, Duncan HF, Rai N, et al. Sodium hypochlorite reduces postoperative discomfort and painful early failure after carious exposure and direct pulp capping-initial findings of a randomized controlled trial[J]. J Clin Med, 2020, 9(8):2408.
[27]	Sabeti M, Huang YJ, Chung YJ, et al. Prognosis of vital pulp therapy on permanent dentition: A systematic review and meta-analysis of randomized controlled trials[J]. J Endod, 2021, 47(11):1683-1695. doi: 10.1016/j.joen.2021.08.008 pmid: 34478787
[28]	Swetha D, Ballal S, Sundar S, et al. The outcome of GaAlAs diode laser(980 nm)pulpotomy in patients with symptomatic irreversible pulpitis assessed using CBCT-randomised controlled trial with an 18-month follow-up[J]. Eur Endod J, 2024, 9(1):35-43.
[29]	Ayhan M, Altunbaş D. Efficacy of potassium titanyl phosphate laser and sodium hypochlorite on postoperative pain intensity following pulpotomy in teeth with symptomatic irreversible pulpitis: A randomized clinical trial[J]. Photobiomodul Photomed Laser Surg, 2023, 41(5):225-233.
[30]	Duncan HF, Kirkevang LL, Peters OA, et al. Treatment of pulpal and apical disease: The European Society of Endodontology(ESE)S3-level clinical practice guideline[J]. Int Endod J, 2023, 56(Suppl 3):238-295.
[31]	Berman LH, Hargreaves KM. Cohen’s pathways of the pulp[M]. 12th ed. Amsterdam: Elsevier Health Sciences, 2020.
[32]	Linsuwanont P, Wimonsutthikul K, Pothimoke U, et al. Treatment outcomes of mineral trioxide aggregate pulpotomy in vital permanent teeth with carious pulp exposure: The retrospective study[J]. J Endod, 2017, 43(2):225-230. doi: S0099-2399(16)30754-3 pmid: 28041685
[33]	Reeves R, Stanley HR. The relationship of bacterial penetration and pulpal pathosis in carious teeth[J]. Oral Surg Oral Med Oral Pathol, 1966, 22(1):59-65.
[34]	Philip N, Suneja B. Minimally invasive endodontics: A new era for pulpotomy in mature permanent teeth[J]. Br Dent J, 2022, 233(12):1035-1041.
[35]	Mutluay M, Arıkan V, Sarı S, et al. Does achievement of hemostasis after pulp exposure provide an accurate assessment of pulp inflammation?[J]. Pediatr Dent, 2018, 40(1):37-42. pmid: 29482681
[36]	汪俊. 不可复性牙髓炎恒牙的活髓保存治疗[J]. 华西口腔医学杂志, 2023, 41(6):622-627.
[37]	Parirokh M, Torabinejad M, Dummer PMH. Mineral trioxide aggregate and other bioactive endodontic cements: An updated overview-part Ⅰ: Vital pulp therapy[J]. Int Endod J, 2018, 51(2):177-205. doi: 10.1111/iej.12841 pmid: 28836288
[38]	Duncan HF, El-Karim I, Dummer PMH, et al. Factors that influence the outcome of pulpotomy in permanent teeth[J]. Int Endod J, 2023, 56(Suppl 2):62-81.
[39]	Al-Asmar AA, Al-Hiyasat AS, Abu-Awwad M, et al. Reframing perceptions in restorative dentistry: Evidence-based dentistry and clinical decision-making[J]. Int J Dent, 2021, 2021: 4871385.
[40]	Alfaisal Y, Idris G, Peters OA, et al. Vital pulp therapy-Factors influencing decision-making for permanent mature teeth with irreversible pulpitis: A systematic review[J]. Int Endod J, 2024, 57(5):505-519.
[41]	Li MJ, Hu XL, Li XL, et al. Dentist-related factors influencing the use of vital pulp therapy: A survey among dental practitioners in China[J]. J Int Med Res, 2019, 47(6):2381-2393. doi: 10.1177/0300060519843406 pmid: 30991868
[42]	Wolters WJ, Duncan HF, Tomson PL, et al. Minimally invasive endodontics: A new diagnostic system for assessing pulpitis and subsequent treatment needs[J]. Int Endod J, 2017, 50(9):825-829. doi: 10.1111/iej.12793 pmid: 28776717
[43]	Hashem D, Mannocci F, Patel S, et al. Clinical and radiographic assessment of the efficacy of calcium silicate indirect pulp capping: A randomized controlled clinical trial[J]. J Dent Res, 2015, 94(4):562-568. doi: 10.1177/0022034515571415 pmid: 25710953
[44]	Careddu R, Duncan HF. A prospective clinical study investigating the effectiveness of partial pulpotomy after relating preoperative symptoms to a new and established classification of pulpitis[J]. Int Endod J, 2021, 54(12):2156-2172. doi: 10.1111/iej.13629 pmid: 34490637
[45]	Huang X, Chen K. Differential expression of longnoncoding RNAs in normal and inflamed human dental pulp[J]. J Endod, 2018, 44(1):62-72. doi: S0099-2399(17)30966-4 pmid: 29079059
[46]	Zhong S, Zhang SP, Bair E, et al. Differential expression of microRNAs in normal and inflamed human pulps[J]. J Endod, 2012, 38(6):746-752. doi: 10.1016/j.joen.2012.02.020 pmid: 22595106
[47]	Zanini M, Meyer E, Simon S. Pulp inflammation diagnosis from clinical to inflammatory mediators: A systematic review[J]. J Endod, 2017, 43(7):1033-1051. doi: S0099-2399(17)30249-2 pmid: 28527838
[48]	Golbasi F, Erdemir A, Kisa U. Comparison of ADAMTS levels in pulp tissue samples of healthy and symptomatic irreversible pulpitis teeth[J]. J Endod, 2022, 48(4):496-501.
[49]	Brizuela C, Meza G, Mercadé M, et al. Inflammatory biomarkers in dentinal fluid as an approach to molecular diagnostics in pulpitis[J]. Int Endod J, 2020, 53(9):1181-1191. doi: 10.1111/iej.13343 pmid: 32496605
[50]	Mente J, Petrovic J, Gehrig H, et al. A prospective clinical pilot study on the level of matrix metalloproteinase-9 in dental pulpal blood as a marker for the state of inflammation in the pulp tissue[J]. J Endod, 2016, 42(2):190-197. doi: 10.1016/j.joen.2015.10.020 pmid: 26725178
[51]	Sharma R, Kumar V, Logani A, et al. Association between concentration of active MMP-9 in pulpal blood and pulpotomy outcome in permanent mature teeth with irreversible pulpitis-a preliminary study[J]. Int Endod J, 2021, 54(4):479-489. doi: 10.1111/iej.13437 pmid: 33128238
[52]	Ballal NV, Duncan HF, Wiedemeier DB, et al. MMP-9 levels and NaOCl lavage in randomized trial on direct pulp capping[J]. J Dent Res, 2022, 101(4):414-419.
[53]	Ballal NV, Duncan HF, Wiedemeier DB, et al. 4-year pulp survival in a randomized trial on direct pulp capping[J]. J Endod, 2024, 50(1):4-9.
[54]	Li M, Tian J, Xu Z, et al. Histology-based profile of inflammatory mediators in experimentally induced pulpitis in a rat model: Screening for possible biomarkers[J]. Int Endod J, 2021, 54(8):1328-1341. doi: 10.1111/iej.13514 pmid: 33715185
[55]	Swanson WB, Gong T, Zhang Z, et al. Controlled release of odontogenic exosomes from a biodegradable vehicle mediates dentinogenesis as a novel biomimetic pulp capping therapy[J]. J Control Release, 2020, 324: 679-694.
[56]	Duncan HF, Kobayashi Y, Kearney M, et al. Epigenetic therapeutics in dental pulp treatment: Hopes, challenges and concerns for the development of next-generation biomaterials[J]. Bioact Mater, 2023, 27: 574-593. doi: 10.1016/j.bioactmat.2023.04.013 pmid: 37213443
[57]	Liu Z, Chen T, Han QQ, et al. HDAC inhibitor LMK-235 promotes the odontoblast differentiation of dental pulp cells[J]. Mol Med Rep, 2018, 17(1):1445-1452.
[58]	Zeng Q, Zhou C, Li MJ, et al. Concentrated growth factor combined with iRoot BP Plus promotes inflamed pulp repair: An in vitro and in vivo study[J]. BMC Oral Health, 2023, 23(1):225.
[59]	Qiu Y, Tian J, Kong SY, et al. SrCuSi₄O₁₀/GelMA composite hydrogel-mediated vital pulp therapy: Integrating antibacterial property and enhanced pulp regeneration activity[J]. Adv Healthc Mater, 2023, 12(24):e2300546.
[60]	郑颖, 陈雪姣, 王倩. 单向滤膜减压保髓新技术用于不可复性牙髓炎活髓保存治疗1例[J]. 中华口腔医学杂志, 2024, 59(1):85-88.
[61]	中共中央、国务院. “健康中国2030”规划纲要[EB/OL]. (2016-10-25)[2024-3-12]. https://www.gov.cn/zhengce/2016-10/25/content_5124174.htm.

不可复性牙髓炎的活髓保存治疗:生物学基础与临床进展

New advances in vital pulp therapy for the treatment of irreversible pulpitis: From biological basic to clinical perspective

RichHTML

PDF

补充材料

可视化

摘要/Abstract

引用本文

使用本文

图/表 1

参考文献 61

相关文章 15

编辑推荐

Metrics

本文评价

[1]	何垚, 赵振远, 高腾, 林鹏, 陈以任, 宋晓萌. 敲低Sec31A对头颈鳞状细胞癌恶性表型的影响[J]. 口腔医学, 2024, 44(7): 487-493.
[2]	田亮亮, 赵佳雄, 南欣荣. 副腮腺肿瘤的诊疗研究进展[J]. 口腔医学, 2024, 44(5): 397-400.
[3]	姚成靓, 武秀萍. 青少年儿童腺样体肥大的影像学测量诊断与正畸治疗的相关性[J]. 口腔医学, 2024, 44(4): 307-311.
[4]	王雪奎, 孙瑶. 中性粒细胞与牙周炎关系的研究进展[J]. 口腔医学, 2024, 44(4): 292-296.
[5]	田欣, 吴思华, 但红霞, 曾昕, 王冏珂, 陈谦明. 肉芽肿性多血管炎临床表现及诊断新进展[J]. 口腔医学, 2024, 44(3): 209-213.
[6]	张志豪, 杨益, 王月秋, 孙思怡, 陈虹, 舒菲, 刘梅. 克罗恩病和牙周炎的共有免疫相关基因及其作为诊断生物标志物的潜力[J]. 口腔医学, 2024, 44(3): 184-191.
[7]	刘梅, 张磊, 蒲玉梅, 黄晓峰, 徐万田, 孙国文. 口腔颗粒细胞瘤的临床病理分析[J]. 口腔医学, 2024, 44(3): 168-172.
[8]	肖诗梦, 刘翼, 李茂雪, 丁一. 激光辅助伴2型糖尿病牙周炎非手术治疗的疗效评价[J]. 口腔医学, 2024, 44(3): 161-167.
[9]	任佳宇, 任秀云. 氧化应激及抗氧化剂辅助治疗牙周炎的研究进展[J]. 口腔医学, 2024, 44(2): 148-151.
[10]	傅开元, 雷杰. 颞下颌关节紊乱病的分类、诊断及治疗进展[J]. 口腔医学, 2024, 44(1): 6-10.
[11]	肖博林, 张伟, 陈刚. 细胞外囊泡与口腔肿瘤免疫[J]. 口腔医学, 2023, 43(9): 769-774.
[12]	周航帆, 江潞. 病毒感染相关天疱疮[J]. 口腔医学, 2023, 43(9): 854-860.
[13]	李成蹊, 宋卫健. 动态导航技术应用于下颌第二磨牙钙化根管1例[J]. 口腔医学, 2023, 43(9): 832-836.
[14]	杨振泽, 林军. 人工智能在正畸正颌联合治疗的应用及展望[J]. 口腔医学, 2023, 43(8): 747-751.
[15]	黄虹, 李媛, 景秋平, 石逸瑾, 阳胜军, 王东苗. 青少年正畸患者下颌第三磨牙萌出的影响因素研究[J]. 口腔医学, 2023, 43(8): 697-701.